All In Biotech

Drug Trial Radar · NCT07915648

Comparing Nadifloxacin Plus Tretinoin Versus Clindamycin Plus Tretinoin Creams for Mild-to-Moderate Acne

Comparison of Efficacy of Topical Nadifloxacin With Tretinoin Versus Clindamycin With Tretinoin in Mild-to-Moderate Acne.

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 158 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

158

Planned (sponsor's estimate)

Start

Sep 17, 2026

Primary completion

Mar 16, 2027

Study completion Mar 16, 2027

Sponsor

Lead sponsor
Nishtar Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this randomized controlled trial is to compare the effectiveness of two topical combination treatments for mild-to-moderate acne vulgaris: 1% nadifloxacin with 0.025% tretinoin cream versus 1% clindamycin with 0.025% tretinoin cream. The study will be conducted in the Department of Dermatology, Nishtar Hospital, Multan, and will enroll adults aged 18 to 40 years of either gender who are newly diagnosed with mild-to-moderate acne vulgaris. Participants with drug-induced acne, endocrine disorders (such as PCOS), other chronic facial skin conditions, pregnancy or lactation, chronic systemic illness, or known hypersensitivity to the study medications will be excluded. Participants will be randomly assigned to one of two groups, with allocation concealed using sealed opaque envelopes. Group A will apply nadifloxacin plus tretinoin cream, and Group B will apply clindamycin plus tretinoin cream. In both groups, a thin layer of the assigned cream will be applied once daily at bedtime to the whole affected area after washing the face with a mild cleanser. Participants will also be advised to use a non-comedogenic moisturizer and sunscreen and to avoid other acne treatments. Follow-up visits will take place at 4, 8, and 12 weeks, with medication use checked by inspecting returned tubes and side effects (redness, dryness, peeling, burning, itching, allergic reactions) recorded at each visit. At baseline and after 12 weeks of treatment, a consultant dermatologist who is unaware of the treatment assigned will count inflammatory, non-inflammatory, and total lesions and grade acne severity using the Global Acne Grading System. The main outcome is the reduction in the number of inflammatory lesions after 12 weeks. Secondary outcomes are the reduction in non-inflammatory and total lesions, change in acne severity grade, and side effects. The study hypothesizes that the reduction in inflammatory lesions at 12 weeks is greater with nadifloxacin plus tretinoin than with clindamycin plus tretinoin.

Conditions

  • Acne Vulgaris

Interventions

  • nadifloxacinDrug

    Topical 1% nadifloxacin cream

  • Tretinoin Cream 0.025%Drug

    Topical Tretinoin Cream 0.025%

  • ClindamycinDrug

    Topical Clindamycin 1% cream

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction in number of inflammatory acne lesionsTime frame: From randomization to the end of treatment at 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nishtar Medical University and Hospital

    Multan, Punjab Province, Pakistan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.